Recent Press Releases

Actavis Non-GAAP Net Revenue Increases 44% to $4 Billion in Fourth Quarter 2014; Non-GAAP EPS Increases 23% to $3.91; Increases 2015 Standalone Forecast

- Adjusted EBITDA Increases 80% to $1.5 Billion in Fourth Quarter 2014 - - $12.8 Billion Full Year Non-GAAP Net Revenue Increases 48% - - $4.5 Billion Full Year Adjusted EBITDA Increases 99% - -...

Actavis Announces Intention to Adopt "Allergan" Corporate Name

- Unites Global Brand Portfolio Under Allergan Name - - Retains Actavis Name for Select Geographic Regions and Product Portfolios- - Recognizes Heritage and Customer Equity of Both Names - - Company...

ASTRAZENECA ANNOUNCES NON-EXECUTIVE BOARD CHANGES

AstraZeneca today announced that Dr Cornelia (Cori) Bargmann will be proposed to shareholders for election as a Non-Executive Director at the Company's Annual General Meeting (AGM) on 24 April 2015....

Actavis to Divest Pharmatech to TPG

-- TPG to Focus Company on Growth and Development of Innovative Products-- --Divestiture Allows Actavis to Sharpen Focus on Supporting Existing Global Supply Chain Network-- DUBLIN, IRELAND...

NICE issues final draft guidance on pomalidomide for blood cancer

NICE issues final draft guidance on pomalidomide for blood cancer NICE has issued final draft guidance not recommending pomalidomide, also known as Imnovid, for treating multiple myeloma. Multiple...

ABBVIE SUBMITS NEW DRUG APPLICATION IN JAPAN FOR ITS INVESTIGATIONAL, ALL-ORAL, TREATMENT FOR CHRONIC HEPATITIS C

- SUBMISSION BASED ON PHASE 3 GIFT-I STUDY IN PATIENTS WITH GENOTYPE 1B CHRONIC HEPATITIS C VIRUS INFECTION - GIFT-I MET ITS PRIMARY ENDPOINT, ACHIEVING 95 PERCENT SUSTAINED VIROLOGIC RESPONSE RATE...

Students with Type 1 Diabetes Get a Boost from Lilly Diabetes to Attend College

Lilly Diabetes supports scholarships through donation to Diabetes Scholars Foundation

ROLLING MEADOWS, Ill. and

Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon

02/10/2015 LAVAL, Quebec, Feb. 10, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that they have been advised by Dendreon Corporation that...

Leading US Companies Announce Major Healthcare Investment in London

LONDON, February 9, 2015 /PRNewswire/ -- London's status as a leading centre for the life sciences, financial and digital industries has attracted significant new investment by two leading US...

Pfenex And Hospira Announce Collaboration To Develop And Commercialize Proposed LUCENTIS® Biosimilar

SAN DIEGO and LAKE FOREST, Ill., Feb. 10, 2015 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira,...

Zydus Cadila Net Profit up by 52% in Q3

For the third quarter ended 31st December 2014, Cadila Healthcare Limited registered a Net Profit of Rs. 282 crores, up by 52% from Rs. 186 crores in the corresponding period last year. The company...

Roche acquires Signature Diagnostics to advance translational research for next generation sequencing (NGS) diagnostics

Roche will leverage Signature's unique expertise in both biobanks and NGS assays to develop novel diagnostics for cancer patients

PLEASAN

FDA approves Roche's Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema

FDA approves Roche's Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema First eye medicine approved for treatment of diabetic...

Novo Nordisk A/S seeks an initial public offering of NNIT

Bagsværd, Denmark, 9 February 2015 - Novo Nordisk A/S today announced the decision to seek an Initial Public Offering (IPO) of NNIT A/S on NASDAQ OMX Copenhagen A/S (Nasdaq Copenhagen). NNIT is...

HOSPIRA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of the Hospira, Inc. Board of Directors in Connection to the Proposed Sale of the Company to Pfizer, Inc. - HSP

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hospira, Inc.

HOSPIRA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of the Hospira, Inc. Board of Directors in Connection to the Proposed Sale of the Company to Pfizer, Inc. - HSP

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hospira, Inc.

Lilly to Present at Leerink Global Healthcare Conference

INDIANAPOLIS, Feb.